6597-47-3

Usage

Uses

Used in Organic Synthesis:
2,4-Pentadien-1-one, 5-[4-(dimethylamino)phenyl]-1-(4-methoxyphenyl)is used as a reagent in organic synthesis for its ability to participate in a wide range of chemical reactions. Its α,β-unsaturated ketone structure allows for versatile applications in the formation of new compounds and materials.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2,4-Pentadien-1-one, 5-[4-(dimethylamino)phenyl]-1-(4-methoxyphenyl)is used as an intermediate in the development of new drugs. Its unique properties make it a promising candidate for the synthesis of potential therapeutic agents, contributing to the advancement of medicine.
Used in Material Development:
2,4-Pentadien-1-one, 5-[4-(dimethylamino)phenyl]-1-(4-methoxyphenyl)is also utilized in the development of new materials, thanks to its chemical reactivity and potential for creating novel structures. This application can lead to the creation of innovative products with improved properties in various industries.
Safety Considerations:
It is important to handle 2,4-Pentadien-1-one, 5-[4-(dimethylamino)phenyl]-1-(4-methoxyphenyl)with care, as it can be hazardous if not used properly. Proper safety measures and precautions should be taken to minimize risks associated with its use in research and industrial applications.

Upstream product

• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 6203-18-5 p-dimethylaminocinnamaldehyde 

Relevant academic research and scientific papers

Design, synthesis and bioactivity of chalcones and its analogues

The Vernohia anthelmintica L.'s extract is one of the most popular Uygur medicines used for vitiligo. It is believed that the chalcone compounds of the plant play an important role in the treatment since they may activate tyrosinase and improve melanin production. In this study, twenty-one chalcones and nine analogues were synthesized in view of three different components of chalcone (A, B ring and α, β-unsaturated carbonyl). After biological evaluation of their activity on tyrosinase in cell-free systems, the result showed that most compounds (except polyhydroxy chalcones) possess activator effect on the tyrosinase, especially for 13a–15a, 20a and 1b, which bearing a comparable activity to the positive control 8-MOP. SAR of these tyrosinase activator was summed up for the first time as well. Finally, compound 13a was found to increase melanin contents and tyrosinase activity 1.75 and 1.3 fold, respectively, compared with that of untreated murine B16 cells at the concentration of 40?μg/mL.

Synthesis, biological evaluation and QSAR studies of diarylpentanoid analogues as potential nitric oxide inhibitors

A series of forty-five 1,5-diphenylpenta-2,4-dien-1-one analogues were synthesized and evaluated for their nitric oxide (NO) inhibition activity in IFN-γ/LPS-activated RAW 264.7 cells. Compounds 3h, 7a, 7d and 7e exhibited comparable or significantly higher activity than the standard, curcumin (IC50 = 14.69 ± 0.24 μM). Compound 7d, a 5-methylthiophenyl-bearing analogue, displayed the most promising NO-inhibitory activity with an IC50 value of 10.24 ± 0.62 μM. The 2D and 3D QSAR analyses performed revealed that a para-hydroxyl group on ring B and an α,β-unsaturated ketone moiety on the linker are crucial for a remarkable anti-inflammatory activity. Based on ADMET and TOPKAT analyses, compounds 3h, 7a and 7d are predicted to be nonmutagenic and to exhibit high blood-brain barrier (BBB) penetration, which indicates that they are potentially effective drug candidates for treating central nervous system (CNS) related disorders.